Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

Abstract

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab, underwent magnetic resonance imaging (MRI) and clinical monitoring during washout and after ocrelizumab starting. During the first 3 months, disease reactivation was observed in five (12%) patients; 6 months after ocrelizumab starting, no further relapses were recorded, and Expanded Disability Status Scale (EDSS) remained stable in 38 (90%) patients. In conclusion, ocrelizumab could be considered a choice to mitigate the risk of disease reactivation in patients previously treated with natalizumab-EID.

Keywords

Natalizumab extend interval dosing (EID)ocrelizumab switching

Get full access to this article

View all access options for this article.

References

Prosperini

Kinkel

Miravalle

, et al. Post-natalizumab disease reactivation in multiple sclerosis: Systematic review and meta-analysis. Ther Adv Neurol Disord 2019; 12: 1756286419837809.

Alping

Frisell

Novakova

, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79(6): 950–958.

Clerico

De Mercanti

Signori

, et al. Extending the interval of natalizumab dosing: Is efficacy preserved? Neurotherapeutics 2019; 17: 200–207.

Zhovtis Ryerson

Frohman

Foley

, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87(8): 885–889.

Zhovtis Ryrson

Folery

Chang

, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019; 93: e1452–e1462.

Kim

S-H

Hyun

J-W

Kim

HJ.

Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Neurochem Int 2019; 130: 104347.

P-R

Koendgen

Campbell

, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 1616(11): 925925–933933.

Scarpazza

De Rossi

Tabiadon

, et al. Four cases of natalizumab-related PML: A less severe course in extended interval dosing? Neurol Sci 2019; 40(10): 2119–2124.

Plavina

Muralindharan

Kuesters

, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017; 89: 1584–1593.

10.

Berger

Malik

Lacey

, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: A rare event. J Neurovirol 2018; 24(3): 323–331.

11.

Krumbholz

Meinl

Kümpfel

, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350–1354.

12.

Barkhof

Ludwing

Wolinsky

, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology 2019; 93: e1778–e1786.

13.

Smoot

Chen

Gervasi-Follmar

, et al. Evaluating the efficacy and safety of transitioning patients from natalizumab to ocrelizumab (OCTAVE) (P3.2-056). Neurology 2019; 92(15 Supplement): P3.2-056.